Cargando…
The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536271/ https://www.ncbi.nlm.nih.gov/pubmed/28759599 http://dx.doi.org/10.1371/journal.pone.0182088 |
_version_ | 1783253987885056000 |
---|---|
author | Salvi, Virginio Grua, Ilaria Cerveri, Giancarlo Mencacci, Claudio Barone-Adesi, Francesco |
author_facet | Salvi, Virginio Grua, Ilaria Cerveri, Giancarlo Mencacci, Claudio Barone-Adesi, Francesco |
author_sort | Salvi, Virginio |
collection | PubMed |
description | BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpretation of these results difficult. Moreover, very recent studies provided conflicting results. Given the high prevalence of both diabetes and AD use in many countries, clarifying whether this association is causal is of extreme relevance for the public health. The aim of the present study is to provide an up-to-date evaluation of the evidence in support of a causal role of ADs in inducing diabetes. METHODS AND FINDINGS: A systematic literature search was conducted to identify relevant studies in MEDLINE (PubMed), PsycINFO, and International Pharmaceutical Abstracts (IPA) through 31(st) December 2016. Only studies assessing the incidence of new-onset diabetes in subjects treated with ADs were included. Results were pooled using a random-effects meta-analysis. Moreover, we extensively reviewed the role of the different sources of bias that have been proposed to explain the association between AD and diabetes. Twenty studies met the inclusion criteria. In the meta-analysis, the association between AD use and diabetes was still evident after the inclusion of the recent negative studies [pooled relative risk = 1.27, 95% confidence interval (CI), 1.19–1.35; p<0.001]. None of the biases proposed by previous authors seemed able to fully explain the observed association. CONCLUSIONS: This updated meta-analysis confirms the association between AD use and incident diabetes. It still remains a matter of debate whether single ADs exert a different effect on the risk of diabetes. Given the possible heterogeneity, we suggest that a classification of ADs according to their pharmacological profiles could be useful in better elucidating the nature of this association. |
format | Online Article Text |
id | pubmed-5536271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55362712017-08-07 The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis Salvi, Virginio Grua, Ilaria Cerveri, Giancarlo Mencacci, Claudio Barone-Adesi, Francesco PLoS One Research Article BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpretation of these results difficult. Moreover, very recent studies provided conflicting results. Given the high prevalence of both diabetes and AD use in many countries, clarifying whether this association is causal is of extreme relevance for the public health. The aim of the present study is to provide an up-to-date evaluation of the evidence in support of a causal role of ADs in inducing diabetes. METHODS AND FINDINGS: A systematic literature search was conducted to identify relevant studies in MEDLINE (PubMed), PsycINFO, and International Pharmaceutical Abstracts (IPA) through 31(st) December 2016. Only studies assessing the incidence of new-onset diabetes in subjects treated with ADs were included. Results were pooled using a random-effects meta-analysis. Moreover, we extensively reviewed the role of the different sources of bias that have been proposed to explain the association between AD and diabetes. Twenty studies met the inclusion criteria. In the meta-analysis, the association between AD use and diabetes was still evident after the inclusion of the recent negative studies [pooled relative risk = 1.27, 95% confidence interval (CI), 1.19–1.35; p<0.001]. None of the biases proposed by previous authors seemed able to fully explain the observed association. CONCLUSIONS: This updated meta-analysis confirms the association between AD use and incident diabetes. It still remains a matter of debate whether single ADs exert a different effect on the risk of diabetes. Given the possible heterogeneity, we suggest that a classification of ADs according to their pharmacological profiles could be useful in better elucidating the nature of this association. Public Library of Science 2017-07-31 /pmc/articles/PMC5536271/ /pubmed/28759599 http://dx.doi.org/10.1371/journal.pone.0182088 Text en © 2017 Salvi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Salvi, Virginio Grua, Ilaria Cerveri, Giancarlo Mencacci, Claudio Barone-Adesi, Francesco The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title | The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title_full | The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title_fullStr | The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title_full_unstemmed | The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title_short | The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis |
title_sort | risk of new-onset diabetes in antidepressant users – a systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536271/ https://www.ncbi.nlm.nih.gov/pubmed/28759599 http://dx.doi.org/10.1371/journal.pone.0182088 |
work_keys_str_mv | AT salvivirginio theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT gruailaria theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT cerverigiancarlo theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT mencacciclaudio theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT baroneadesifrancesco theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT salvivirginio riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT gruailaria riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT cerverigiancarlo riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT mencacciclaudio riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis AT baroneadesifrancesco riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis |